Abstract
Mesenchymal stem cells (MSCs) now are popular stem cells for clinical applications. To date, MSCs were accepted in various disease treatments with several FDA approved treatments in some countries. One important requirement for the clinical usage of stem cells is the production of stem cells. Actually, the treatment efficacy of MSC transplantation depends on the quality of transplanted MSCs. This review aimed to present some guidelines for MSC production according to good manufacturing practice that helps to maintain the quality of stem cells from batch to batch as well as the clinical satisfaction.
Highlights
Stem cell transplantation is a novel treatment method for many diseases, especially degenerative diseases
There are more than 20 diseases that can be treated by Mesenchymal stem cells (MSCs) transplantation, researchers have focused on two groups of diseases: degenerative and PROGRESS IN STEM CELL 2016, 3(2): 87-96 immune system-related diseases
Kasten et al showed that bone marrow-derived MSCs grown in medium supplemented with platelet lysate (PL) commit to an osteoblastic lineage (Kasten et al, 2008), whereas Van Pham et al (2013) showed that platelet rich plasma (PRP) drives ADSC differentiation into chondroblasts(Van Pham et al, 2013)
Summary
Stem cell transplantation is a novel treatment method for many diseases, especially degenerative diseases. There are reports of the clinical application of stem cells for more than 70 diseases. Commercialized MSC-based products have been developed and approved as stem cell drugs in some countries (Table 2). These media are simple, inexpensive, and convenient for ex vivo MSC culture, they contain a xenogeneic source of GFs and proteins (from FCS) with a high risk of disease transmission.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
